Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Bausch Lomb Corporation (BLCO.TO)

Bausch Lomb Corporation (BLCO.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Bausch Lomb Corporation 520 Applewood Crescent Vaughan ON L4K 4B4 CAN

https://www.bausch.com P: 905-695-7700

Description:

Bausch & Lomb is one of the largest vision care companies in the U.S. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market which B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Key Statistics

Overview:

Market Capitalization, $K 9,075,383
Shares Outstanding, K 351,895
Annual Sales, $ 4,146 M
Annual Net Income, $ -260,000 K
Last Quarter Sales, $ 1,216 M
Last Quarter Net Income, $ -151,000 K
% of Institutional Shareholders 2.75%

Growth:

1-Year Return 9.71%
3-Year Return 0.00%
5-Year Return 0.00%
5-Year Revenue Growth 2.50%

Per-Share Information:

Most Recent Earnings -0.43 on 08/01/24
Next Earnings Date N/A
Earnings Per Share ttm -1.29
EPS Growth vs. Prev Year 222.70%
Dividend Payout Ratio 0.00%

BLCO.TO Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward 26.11
Price/Earnings to Growth N/A
Return-on-Equity % -6.77%
Return-on-Assets % -3.71%
Profit Margin % -6.27%
Debt/Equity 0.66
Price/Sales 1.50
Price/Book 1.02
Book Value/Share 25.24
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar